Search

Your search keyword '"M.F. Osti"' showing total 33 results
Start Over Author "M.F. Osti"
33 results on '"M.F. Osti"'

1. OC-0272 External validation of the Hemo-Eosinophils-Inflammation index as a prognosticator in anal cancer

Author

P. Franco, A. Porreca, M. Di Nicola, G. Mantello, F. Valvo, N. Slim, S. Manfrida, M.A. Gambacorta, F. De Felice, S. Vagge, M. Krengli, E. Palazzari, M.F. Osti, A. Gonelli, G. Catalano, P. Pittoni, M. Lupattelli, M.R. Niespolo, M.E. Rosetto, G. Macchia, O. Durante, F. Munoz, R.M. D'Angelillo, D. Genovesi, and L. Caravatta

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology
Published
2022
Full Text
View/download PDF

2. SBRT for Nodal Metastasis

Author

D. Caivano, R.C. Sigillo, M. Rotondi, I. Angelicone, M. Valeriani, and M.F. Osti

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

3. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

Author

L. Nicosia, D. Franceschini, F. Perrone-Congedi, F. Casamassima, M.A. Gerardi, M. Rigo, R. Mazzola, M. Perna, V. Scotti, A. Fodor, A. Iurato, F. Pasqualetti, G. Gadducci, S. Chiesa, R.M. Niespolo, A. Bruni, G. Alicino, L. Frassinelli, P. Borghetti, A. Di Marzo, A. Ravasio, B. De Bari, M. Sepulcri, D. Aiello, G. Mortellaro, C. Sangalli, M. Franceschini, G. Montesi, F.M. Aquilanti, G. Lunardi, R. Valdagni, I. Fazio, Giovanni Scarzello, L. Corti, V. Vavassori, E. Maranzano, S.M. Magrini, S. Arcangeli, Maria Antonietta Gambacorta, V. Valentini, F. Paiar, S. Ramella, N.G. Di Muzio, L. Livi, B.A. Jereczek-Fossa, M.F. Osti, M. Scorsetti, F. Alongi, Nicosia, L, Franceschini, D, Perrone-Congedi, F, Casamassima, F, Gerardi, M, Rigo, M, Mazzola, R, Perna, M, Scotti, V, Fodor, A, Iurato, A, Pasqualetti, F, Gadducci, G, Chiesa, S, Niespolo, R, Bruni, A, Alicino, G, Frassinelli, L, Borghetti, P, Di Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Lunardi, G, Valdagni, R, Fazio, I, Scarzello, G, Corti, L, Vavassori, V, Maranzano, E, Magrini, S, Arcangeli, S, Gambacorta, M, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, and Alongi, F

Subjects
medicine.medical_specialty, Multivariate analysis, Colorectal cancer, medicine.medical_treatment, SABR volatility model, Oligometastatic disease, Predictive factors, SABR, SBRT, Stereotactic ablative radiotherapy, Retrospective database, Ablative case, medicine, Radiology, Nuclear Medicine and imaging, Lung, business.industry, Hematology, medicine.disease, Radiation therapy, medicine.anatomical_structure, Oncology, Radiology, Predictive factor, business
Abstract

Introduction: Stereotactic ablative radiotherapy (SABR) has been shown to increase survival in oligometastatic disease, but local control of colorectal metastases remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate the progression to the polymetastatic disease (PMD). Material and methods: The study involved 23 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1033 lung metastases were reported. Clinical and biological parameters were evaluated as predictive for freedom from local progression-free survival (FLP). Secondary end-point was the time to the polymetastatic conversion (tPMC). Results: Two-year FLP was 75.4%. Two-year FLP for lesions treated with a BED < 00 Gy, 100–124 Gy, and ≥125 Gy was 76.1%, 70.6%, and 94% (p = 0.000). Two-year FLP for lesion measuring ≤10 mm, 10–20 mm, and >20 mm was 79.7%, 77.1%, and 66.6% (p = 0.027). At the multivariate analysis a BED ≥125 Gy significantly reduced the risk of local progression (HR 0.24, 95%CI 0.11–0.51; p = 0.000). Median tPMC was 26.8 months. Lesions treated with BED ≥125 Gy reported a significantly longer tPMC as compared to lower BED. The median tPMC for patients treated to 1, 2–3 or 4–5 simultaneous oligometastases was 28.5, 25.4, and 9.8 months (p = 0.035). Conclusion: The present is the largest series of lung colorectal metastases treated with SABR. The results support the use of SBRT in lung oligometastatic colorectal cancer patients as it might delay the transition to PMD or offer relatively long disease-free period in selected cases. Predictive factors were identified for treatment personalization.

Published
2022

7. OC-0602 A pREDictive model of polymetastatic disease on oligometastatic colorectal cancer: the RED LaIT-SABR

Author

L. Nicosia, D. Franceschini, F. Perrone Congedi, F. Casamassima, M.A. Gerardi, M. Rigo, R. Mazzola, M. Perna, V. Scotti, A. Fodor, A. Iurato, F. Pasqualetti, G. Gadducci, S. Chiesa, R.M. Niespolo, A. Bruni, G. Alicino, L. Frassinelli, P. Borghetti, A. Di Marzo, A. Ravasio, B. De Bari, M. Sepulcri, D. Aiello, G. Mortellaro, C. Sangalli, M. Franceschini, G. Montesi, F.M. Aquilanti, G. Lunardi, R. Valdagni, I. Fazio, L. Corti, V. Vavassori, E. Maranzano, S.M. Magrini, S. Arcangeli, V. Valentini, F. Paiar, S. Ramella, N.G. Di Muzio, L. Livi, B.A. Jereczek- Fossa, M.F. Osti, M. Scorsetti, and F. Alongi

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology
Published
2022
Full Text
View/download PDF

10. PH-0112 Multicenter large retrospectIve database on SBRT for colorectal lung metastases: the LaIT-SABR study

Author

Riccardo Valdagni, L. Vavassori, Michele Rigo, Marianna Alessandra Gerardi, B. De Bari, N. Di Muzio, Barbara Alicja Jereczek-Fossa, Vieri Scotti, Frank Lohr, M. Perna, Filippo Alongi, Luigi Corti, I. Fazio, R.M. Niespolo, G. Mortellaro, F.M. Aquilanti, Andrei Fodor, Paolo Borghetti, M.F. Osti, Luca Nicosia, A. Ravasio, Davide Franceschini, L. Frassinelli, A. Di Marzo, G. Gadducci, A. Iurato, Fabiola Paiar, D. Aiello, Alessio Bruni, F. Casamassima, Sara Ramella, Silvia Chiesa, Rosario Mazzola, F. Perrone Congedi, Stefano Arcangeli, Stefano Maria Magrini, M. Franceschini, Lorenzo Livi, M. Sepulcri, Francesco Pasqualetti, Claudia Sangalli, Marta Scorsetti, Ernesto Maranzano, Giampaolo Montesi, and V. Valentini

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, SABR volatility model, Retrospective database
Published
2021
Full Text
View/download PDF

11. PO-1169 30 Gy single dose stereotactic radiation therapy in a series of patients with lung oligometastasis

Author

M.F. Osti, Maurizio Valeriani, F. Perrone, A.M. Ascolese, Barbara Campanella, Dimitri Anzellini, and Giovanna Scalabrino

Subjects
Series (stratigraphy), Lung, medicine.anatomical_structure, Oncology, business.industry, medicine.medical_treatment, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Stereotactic radiation therapy, Nuclear medicine, business
Published
2021
Full Text
View/download PDF

13. A Multicenter Large Retrospective Database On The Personalization Of Stereotactic Ablative Radiotherapy For Lung Metastases From Colon-rectal Cancer: Early Results From The LaIT-SABR Study

Author

S. Slimani, A. Ravasio, Stefano Maria Magrini, L. Frassinelli, B. De Bari, M.F. Osti, Michele Rigo, Ernesto Maranzano, V. Vavassori, Paolo Borghetti, Marta Scorsetti, Alessio Bruni, Davide Franceschini, Filippo Alongi, Rosario Mazzola, F. Perrone, Frank Lohr, A. Di Marzo, and Luca Nicosia

Subjects
Cancer Research, medicine.medical_specialty, Radiation, Lung, business.industry, medicine.medical_treatment, SABR volatility model, Retrospective database, Personalization, Radiation therapy, medicine.anatomical_structure, Oncology, Early results, Ablative case, Colon rectal cancer, medicine, Radiology, Nuclear Medicine and imaging, Radiology, business
Published
2020
Full Text
View/download PDF

14. 30 GY SINGLE HIGH DOSE STEREOTACTIC BODY RADIOTHERAPY IN THE TREATMENT OF PRIMARY LUNG TUMORS: LONG TERM RESULTS

Author

M.F. Osti, Chiara Reverberi, Luca Nicosia, V. De Sanctis, Linda Agolli, and Maurizio Valeriani

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Lung, medicine.anatomical_structure, business.industry, Single high dose, Medicine, Radiology, Long term results, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, business, Stereotactic body radiotherapy
Published
2020
Full Text
View/download PDF

15. PO-0781 30 Gy single dose SBRT: Outcome in a large series of patients with lung oligometastatic disease

Author

Enrico Cortesi, M.F. Osti, Chiara Reverberi, Luca Nicosia, Stefano Bracci, C. De Dominicis, Linda Agolli, V. De Sanctis, M F Martelli, Maurizio Valeriani, and Lucio Marinelli

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, Oncology, business.industry, Medicine, Large series, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, Outcome (game theory), Oligometastatic disease
Published
2019
Full Text
View/download PDF

16. EP-1610: Oligoprogression during Abiraterone therapy treated with radiotherapy in mCRPC patients

Author

C. Proietti, M.F. Osti, Maurizio Valeriani, Paolo Marchetti, Luca Nicosia, S. Giacinti, G. Arrivi, Giulia Poti, V. De Sanctis, Chiara Reverberi, Stefano Maria Magrini, Lucio Marinelli, and Anna Maria Aschelter

Subjects
Radiation therapy, Oncology, Abiraterone, chemistry.chemical_compound, medicine.medical_specialty, chemistry, Internal medicine, medicine.medical_treatment, medicine, Radiology, Nuclear Medicine and imaging, Hematology
Published
2018
Full Text
View/download PDF

18. Fractionated Stereotactic Body Radiotherapy (SBRT) Versus Single Dose Stereotactic Body Radiotherapy in the Treatment of Primary Lung Tumors: Early Results from a Multi-Institutional Analysis

Author

Michele Rigo, Francesco Ricchetti, Rosario Mazzola, Chiara Reverberi, Filippo Alongi, Luca Nicosia, M.F. Osti, Maurizio Valeriani, Vanessa Figlia, and Niccolò Giaj-Levra

Subjects
Cancer Research, medicine.medical_specialty, Radiation, Lung, medicine.anatomical_structure, Oncology, Early results, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, business, Stereotactic body radiotherapy
Published
2019
Full Text
View/download PDF

21. EP-1248: Lung re-irradiation with stereotactic body radiation therapy (SBRT)

Author

Claudia Scaringi, Maurizio Valeriani, Giuseppe Minniti, Paolo Bonome, V. De Sanctis, and M.F. Osti

Subjects
Re-Irradiation, Lung, medicine.anatomical_structure, Oncology, business.industry, Stereotactic body radiation therapy, Radiology Nuclear Medicine and imaging, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Nuclear medicine
Published
2016
Full Text
View/download PDF

22. PO-0666: 30 Gy single-dose SBRT to lung lesions: outcome in a large series of patients

Author

C. De Dominicis, Enrico Cortesi, Chiara Reverberi, V. De Sanctis, Linda Agolli, Giuseppe Minniti, Luca Nicosia, M.F. Osti, M F Martelli, and Maurizio Valeriani

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, Oncology, business.industry, medicine, Large series, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, Outcome (game theory)
Published
2017
Full Text
View/download PDF

23. EP-1320: Feasibility and efficacy of stereotactic radiotherapy in lymph-node metastases

Author

Linda Agolli, Luca Nicosia, Maurizio Valeriani, Stefano Bracci, Giuseppe Minniti, V. De Sanctis, R. Maurizi Enrici, and M.F. Osti

Subjects
Stereotactic radiotherapy, medicine.medical_specialty, medicine.anatomical_structure, Oncology, business.industry, Radiology Nuclear Medicine and imaging, Physical therapy, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, Hematology, business, Lymph node
Published
2015
Full Text
View/download PDF

24. EP-1141: Second cancer in Primary Mediastinal Lymphoma treated with MACOP-B ± R and mediastinal radiotherapy

Author

A. Ansuinelli, V. De Sanctis, M F Martelli, Giuseppe Minniti, L. Grapulin, M.F. Osti, Eleonora Russo, Daniela Musio, Maurizio Valeriani, Alessandra Spagnoli, Vincenzo Tombolini, Marco Alfò, A. Di Rocco, Maria Luisa Moleti, and Stefano Bracci

Subjects
medicine.medical_specialty, genetic structures, business.industry, medicine.medical_treatment, digestive, oral, and skin physiology, Second cancer, Hematology, digestive system diseases, Radiation therapy, Oncology, immune system diseases, Radiology Nuclear Medicine and imaging, Primary Mediastinal Lymphoma, hemic and lymphatic diseases, medicine, Radiology, Nuclear Medicine and imaging, Radiology, business
Published
2016
Full Text
View/download PDF

25. Intermediate Risk Prostate Cancer Patients Treated With Image Guided Hypofractionated Radiation Therapy

Author

Donatella Caivano, V. De Sanctis, Paolo Bonome, Manuela Giuliani, M.F. Osti, and Maurizio Valeriani

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Prostate cancer, Radiation, Hypofractionated Radiation Therapy, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, medicine.disease
Published
2017
Full Text
View/download PDF

26. Comparision between transrectal ultrasonography and computed tomography with rectal inflation of gas in preoperative staging of lower rectal cancer

Author

S. Sbarbati, C. Pirolli, C. Meli, F. Scattoni Padovan, Vincenzo Tombolini, R. Maurizi Enrici, and M.F. Osti

Subjects
Adult, Male, medicine.medical_specialty, Rectum, urologic and male genital diseases, Sensitivity and Specificity, Endosonography, Preoperative Care, medicine, Humans, Radiology, Nuclear Medicine and imaging, Large intestine, Aged, Neoplasm Staging, Retrospective Studies, Neuroradiology, medicine.diagnostic_test, Rectal Neoplasms, business.industry, Ultrasound, Interventional radiology, General Medicine, Middle Aged, Pneumoradiography, Prone position, medicine.anatomical_structure, Transrectal ultrasonography, Female, Tomography, Radiology, Tomography, X-Ray Computed, business
Abstract

Computed tomography with rectal air insufflation was compared with transrectal ultrasonography (TRUS) in 63 patients. The CT protocol involved pre- and postcontrast scans with 5 mm slice thickness following air insufflation in IV antiperistaltic agent. Of the patients, 79 % were scanned in the prone position. Results of the preoperative examinations were compared with the histological findings. The CT examination had an accuracy rate of 74 %, predicting perirectal spread with a sensitivity of 83 % and a specificity of 62 %, whereas the corresponding figures for TRUS were 83, 91 and 67 %. The accuracy, sensitivity and specificity of CT and TRUS for nodal involvement were 57, 56, 57, 66, 68 and 64 %-respectively. These findings confirm that TRUS is more accurate than CT in local tumour (T) staging and in detecting nodal (N) spread. However, the appropriate CT technique shows spread of tumour outside the rectal wall and locoregional lymph nodes with reasonable accuracy. Lymphatic spread correlated with nodal size. TRUS and CT correctly staged only 57 and 43 %, respectively, of cases with nodal metastases with maximum diameter of 5 mm. TRUS sometimes overstaged perirectal growth of tumour in 7 patients, due to inflammation (5 patients) or incorrect positioning of the balloon in relation to the tumour surface (2 patients).

Published
1997
Full Text
View/download PDF

27. External-beam radiotherapy and/or HDR brachytherapy in postoperative endometrial cancer patients: clinical outcomes and toxicity rates

Author

S. Narici, Massimo Moscarini, F. Patacchiola, Linda Agolli, Maurizio Valeriani, M.F. Osti, B. Mossa, V. De Sanctis, and R. Maurizi Enrici

Subjects
Adult, Oncology, medicine.medical_specialty, Ovariectomy, medicine.medical_treatment, Brachytherapy, Hysterectomy, Salpingectomy, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, External beam radiotherapy, Neoplasm Metastasis, Survival rate, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Proportional hazards model, business.industry, Radiotherapy Planning, Computer-Assisted, Endometrial cancer, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Endometrial Neoplasms, Survival Rate, Radiation therapy, Treatment Outcome, Chemotherapy, Adjuvant, Lymphatic Metastasis, Female, Radiology, business
Abstract

The objectives of this study were to evaluate local disease control, overall survival (OS), disease-free survival (DFS) and local relapse-free survival (LRFS) in patients with endometrial cancer undergoing adjuvant vaginal brachytherapy (VBT )± external-beam radiotherapy (EBRT).From September 2007 to February 2011, 40 patients with endometrial cancer were retrospectively analysed. Surgery consisted of total hysterectomy and bilateral salpingo-oophorectomy without node dissection (16 patients) or with bilateral pelvic node dissection (24 patients). The stage distribution was as follows: two IA, nine IB, 12 IC, five IIA, eight IIB, two IIIA and two IIIC. Thirty-four patients underwent EBRT and VBT. Six patients received VBT alone.Median follow-up was 26 months. The 5-year OS and DFS were 96.4% and 86.9%, respectively. No local recurrence was observed. Four patients presented distant disease (three had lung metastases and one had hepatic node metastases). Acute EBRT-related toxicities were seen in 15 (38%) patients. We recorded late toxicities in 14 patients (35%). There was no evidence of grade 3-4 toxicity.Adjuvant EBRT and/or VBT in patients with endometrial cancer showed good outcomes in terms of local disease control, with an acceptable toxicity profile.

Published
2013

28. [Curative radiotherapy in patients with anal cancer: clinical outcomes and prognostic factors in a single-institution experience]

Author

Claudia Scaringi, R. Maurizi Enrici, Linda Agolli, Stefano Bracci, M.F. Osti, and Giuseppe Minniti

Subjects
Male, medicine.medical_specialty, Treatment outcome, Prognostic factors, Antineoplastic Combined Chemotherapy Protocols, medicine, Anal cancer, Chemotherapy, Humans, Radiology, Nuclear Medicine and imaging, In patient, Single institution, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, Gynecology, Radiotherapy, business.industry, Disease progression, General Medicine, Middle Aged, medicine.disease, Anus Neoplasms, Prognosis, Combined Modality Therapy, Survival Rate, Treatment Outcome, Disease Progression, Neoplasm staging, Female, business
Abstract

Il nostro obiettivo era quello di analizzare retrospettivamente una serie di pazienti con cancro anale trattati con intento curativo, in termini di sopravvivenza e controllo locale. Quarantadue pazienti con cancro anale sono stati trattati con radioterapia +/− chemioterapia concomitante. e stato valutato l’impatto dei fattori prognostici su sopravvivenza globale (OS), sopravvivenza libera da malattia (DFS), sopravvivenza specifica di malattia (DSS), sopravvivenza libera da colostomia (CFS) e sopravvivenza libera da metastasi (MFS). Lo stadio di malattia era: 9 pazienti stadio I, 15 pazienti stadio II, 4 pazienti stadio IIIA, e 14 stadio IIIB. La progressione/persistenza di malattia si e verificata in 5 pazienti (12%). I valori di OS, DSS, DFS, CFS, MFS a 5 anni sono stati 72,7%, 84,2%, 85,7% 81,1% e 87,1%, rispettivamente. All’analisi univariata, il T e emerso come fattore prognostico significativo per l’OS, DSS, CFS e DFS, mentre l’N e risultato significativo per la DSS. All’analisi multivariata, il T e risultato un fattore significativo per l’OS e la CFS. I nostri dati confermano che la radiochemioterapia nel cancro anale e fattibile e puo fornire un beneficio di sopravvivenza con tossicita accettabili. Dovremmo considerare il T e l’N come importanti fattori prognostici per la sopravvivenza.

Published
2011

29. Palliative radiotherapy for brain metastases

Author

E. Banelli, A. Montagna, Alfredo Zurlo, Enrici Rm, M.F. Osti, and Tombolini

Subjects
Oncology, Hypofractionated Radiotherapy, Cancer Research, medicine.medical_specialty, business.industry, Cancer, General Medicine, medicine.disease, Patient population, Palliative radiotherapy, Internal medicine, Radiological weapon, Overall survival, Medicine, business
Abstract

Several studies have confirmed that results of different hypofractionated radiotherapy schedules for palliative purpose are similar to those of conventional higher doses. From 1992 to 1993, 56 consecutive patients with brain metastases were irradiated at our Institution. Three different schedules were used ranging between 18 and 40 Gy. Overall survival, clinical and radiological responses were evaluated with regard to schedules and prognostic characteristics of patient population. There were no significant differences between the treatments, even though patients with shorter estimated life expectancy were more likely to be irradiated with more hypofractionated radiotherapy. Short, cost effective treatments appear to be the best therapeutic option both for institution and patients in most palliative cases.

Published
1995

30. P59 Radiotherapy in non-Hodgkin's cutaneous lymphomas

Author

Nicola Raffetto, M. Santarelli, M.F. Osti, M Nappa, R. Maurizi Enrici, and Violante Di Donato

Subjects
Radiation therapy, Chemotherapy, medicine.medical_specialty, Hodgkin s, Oncology, Fractionated irradiation, business.industry, medicine.medical_treatment, medicine, Combined therapy, Radiology, Nuclear Medicine and imaging, Radiology, business
Published
1998
Full Text
View/download PDF

31. Radiotherapy alone VS radiotherapy plus chemotherapy (one course ABVD) in stage II pA Hodgkin's disease with mediastinal localization

Author

Vincenzo Tombolini, S. Sbarbati, Biagini C, R. Maurizi Enrici, M.F. Osti, and Anselmo Ap

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Hodgkin s, business.industry, medicine.medical_treatment, Disease, Stage ii, Radiotherapy alone, Radiation therapy, ABVD, Internal medicine, medicine, business, medicine.drug
Published
1993
Full Text
View/download PDF

32. EP-1181: SBRT in oligometastatic/oligorecurrent NSCLC cancer patients: a new therapeutic approach

Author

Stefano Bracci, R. Maurizi Enrici, Luca Nicosia, Giuseppe Minniti, Teresa Falco, V. De Sanctis, M.F. Osti, Maurizio Valeriani, and Linda Agolli

Subjects
Oncology, medicine.medical_specialty, Therapeutic approach, Radiology Nuclear Medicine and imaging, business.industry, Internal medicine, medicine, Cancer, Radiology, Nuclear Medicine and imaging, Hematology, business, medicine.disease
Full Text
View/download PDF

33. EP-1373: Hypofractionated radiotherapy and androgen deprivation in intermediate risk prostate cancer

Author

V. De Sanctis, Stefano Bracci, M.F. Osti, Maurizio Valeriani, L. Bertaccini, and Linda Agolli

Subjects
Hypofractionated Radiotherapy, Oncology, medicine.medical_specialty, medicine.drug_class, business.industry, Hematology, Androgen, medicine.disease, Prostate cancer, Radiology Nuclear Medicine and imaging, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Intermediate risk, business
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results